Persistence of clinically significant portal hypertension after eradication of hepatitis C virus in patients with advanced cirrhosis
C Díez, J Berenguer… - Clinical Infectious …, 2020 - academic.oup.com
C Díez, J Berenguer, L Ibañez-Samaniego, E Llop, L Pérez-Latorre, MV Catalina…
Clinical Infectious Diseases, 2020•academic.oup.comThis prospective study of 34 patients with HCV cirrhosis (17 HIV positive) with baseline
clinically significant portal hypertension (CSPH; HVPG≥ 10 mmHg) and SVR after DAA
therapy showed that disappearance of CSPH (primary endpoint) is a rare event (6/18
patients; 18%), indicating a persistent risk of clinical progression or death.
clinically significant portal hypertension (CSPH; HVPG≥ 10 mmHg) and SVR after DAA
therapy showed that disappearance of CSPH (primary endpoint) is a rare event (6/18
patients; 18%), indicating a persistent risk of clinical progression or death.
Abstract
This prospective study of 34 patients with HCV cirrhosis (17 HIV positive) with baseline clinically significant portal hypertension (CSPH; HVPG ≥10 mmHg) and SVR after DAA therapy showed that disappearance of CSPH (primary endpoint) is a rare event (6/18 patients; 18%), indicating a persistent risk of clinical progression or death.
Oxford University Press以上显示的是最相近的搜索结果。 查看全部搜索结果